ES504575A0 - Procedimiento para preparar isosteros de polipeptidos inhibi dores de renina. - Google Patents

Procedimiento para preparar isosteros de polipeptidos inhibi dores de renina.

Info

Publication number
ES504575A0
ES504575A0 ES504575A ES504575A ES504575A0 ES 504575 A0 ES504575 A0 ES 504575A0 ES 504575 A ES504575 A ES 504575A ES 504575 A ES504575 A ES 504575A ES 504575 A0 ES504575 A0 ES 504575A0
Authority
ES
Spain
Prior art keywords
renine
inhibitive
isosteres
polypeptide
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES504575A
Other languages
English (en)
Other versions
ES8305306A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring Pharmaceuticals Ltd
Ferring AB
Original Assignee
Ferring Pharmaceuticals Ltd
Ferring AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Pharmaceuticals Ltd, Ferring AB filed Critical Ferring Pharmaceuticals Ltd
Publication of ES8305306A1 publication Critical patent/ES8305306A1/es
Publication of ES504575A0 publication Critical patent/ES504575A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/86—Renin inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES504575A 1980-08-06 1981-08-05 Procedimiento para preparar isosteros de polipeptidos inhibi dores de renina. Granted ES504575A0 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8025579 1980-08-06
GB8118194 1981-06-12

Publications (2)

Publication Number Publication Date
ES8305306A1 ES8305306A1 (es) 1983-04-01
ES504575A0 true ES504575A0 (es) 1983-04-01

Family

ID=26276457

Family Applications (1)

Application Number Title Priority Date Filing Date
ES504575A Granted ES504575A0 (es) 1980-08-06 1981-08-05 Procedimiento para preparar isosteros de polipeptidos inhibi dores de renina.

Country Status (9)

Country Link
US (1) US4424207A (es)
EP (1) EP0045665B1 (es)
AU (1) AU549157B2 (es)
DE (1) DE3172138D1 (es)
DK (1) DK349481A (es)
ES (1) ES504575A0 (es)
FI (1) FI812427L (es)
IE (1) IE51471B1 (es)
NO (1) NO812612L (es)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609643A (en) * 1980-08-06 1986-09-02 Aktiebolaget Hassle Renin inhibitors, treatments and dipeptide synthesis
DE3377497D1 (en) * 1982-09-15 1988-09-01 Haessle Ab Enzyme inhibitors
US4650661A (en) * 1982-09-15 1987-03-17 Aktiebolaget Hassle Enzyme inhibitors
US4595677A (en) * 1982-12-03 1986-06-17 Ciba-Geigy Corporation Substituted tetrapeptides
GB2135773B (en) * 1983-01-31 1985-12-04 Boots Celltech Diagnostics Enzyme inhibitor labelled immunoassay
EP0316965A3 (en) * 1983-02-07 1989-08-09 Aktiebolaget Hässle Enzyme inhibitors
GB8322414D0 (en) * 1983-08-19 1983-09-21 Szelke M Renin inhibitors
GB8305985D0 (en) * 1983-03-04 1983-04-07 Szelke M Enzyme inhibition
IT1164239B (it) * 1983-05-25 1987-04-08 Anic Spa Un retro-inverso analogo del decapeptide (5-14)dell'angiotensinogeno equino inibitore specifico della renina con elevata resistenza all'idrolisi enzimatica
US4613676A (en) * 1983-11-23 1986-09-23 Ciba-Geigy Corporation Substituted 5-amino-4-hydroxyvaleryl derivatives
EP0144290A3 (de) * 1983-12-01 1987-05-27 Ciba-Geigy Ag Substituierte Aethylendiaminderivate
JPS60163899A (ja) * 1984-02-03 1985-08-26 Sankyo Co Ltd レニン阻害ペプチド類
DK110285A (da) 1984-03-12 1985-09-13 Pfizer Polypeptider og polypeptidderivater indeholdende statin eller derivater deraf og farmaceutiske praeparater
US4668663A (en) * 1984-03-27 1987-05-26 Merck & Co., Inc. Renin inhibitors containing homophe8
US4661473A (en) * 1984-03-27 1987-04-28 Merck & Co., Inc. Renin inhibitors containing peptide isosteres
EP0156318A3 (en) * 1984-03-27 1988-07-06 Merck & Co. Inc. C-terminal amide cyclic renin inhibitors containing peptide isosteres
US4663310A (en) * 1984-04-04 1987-05-05 Merck & Co., Inc. Renin inhibitors containing 2-substituted statine
EP0163237A3 (en) * 1984-05-29 1988-04-27 Merck & Co. Inc. Di- and tri-peptidal renin inhibitors
US4652551A (en) * 1984-06-22 1987-03-24 Abbott Laboratories Renin inhibiting compounds
US4645759A (en) * 1984-06-22 1987-02-24 Abbott Laboratories Renin inhibiting compounds
EP0173481A3 (en) * 1984-08-06 1988-12-21 The Upjohn Company Peptides
US4880781A (en) * 1984-08-06 1989-11-14 The Upjohn Company Renin inhibitory peptides containing an N-alkyl-histidine moiety
DE3438545A1 (de) * 1984-10-20 1986-04-24 Merck Patent Gmbh, 6100 Darmstadt Peptide
US4616088A (en) * 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4727060A (en) * 1984-11-13 1988-02-23 Ciba-Geigy Corporation Novel 5-amino-4-hydroxyvaleryl derivatives
DE3512128A1 (de) 1985-04-03 1986-10-09 Merck Patent Gmbh, 6100 Darmstadt Peptide
US4882420A (en) * 1985-04-19 1989-11-21 The Upjohn Company Dihalo-statine substituted renin inhibitors
DE3674131D1 (de) 1985-04-19 1990-10-18 Upjohn Co Substituierte dihalo-statin-reninhemmungsmittel.
US4826815A (en) * 1985-05-17 1989-05-02 Abbott Laboratories Renin inhibiting compounds
US4665055A (en) * 1985-06-17 1987-05-12 Merck & Co., Inc. Peptide renin inhibitors
US4777286A (en) * 1985-06-18 1988-10-11 The Upjohn Company Certain aryl or hetero-hydroxamic acid esters useful as renin inhibitors
US4992562A (en) * 1985-08-09 1991-02-12 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
US4729985A (en) 1985-08-09 1988-03-08 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
US4906613A (en) * 1985-11-05 1990-03-06 Schering Corporation Antiglaucoma compositions and methods
US4894437A (en) * 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
DE3540495A1 (de) * 1985-11-15 1987-05-21 Merck Patent Gmbh Aminosaeurederivate
WO1987004349A1 (en) * 1986-01-16 1987-07-30 Joseph Dellaria Peptide analogs
EP0236734A3 (de) * 1986-02-07 1988-05-11 Ciba-Geigy Ag Durch schwefelhaltigen Gruppen substituierte 5-Amino-4-hydroxyvalerylderivate
CA1309555C (en) * 1986-02-27 1992-10-27 Suvit Thaisrivongs Inhibiting peptides having a dihydroxyethylene isostere transitionstate insert
US4705846A (en) * 1986-03-27 1987-11-10 The Upjohn Company Novel renin inhibiting peptides having a gamma lactam pseudo dipeptide insert
US4743584A (en) * 1986-10-07 1988-05-10 Merck & Co., Inc. C-terminal amide cyclic renin inhibitors containing peptide isosteres
EP0264106B1 (en) * 1986-10-14 1994-03-16 Banyu Pharmaceutical Co., Ltd. 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use
US4743585A (en) * 1986-11-21 1988-05-10 Warner-Lambert Company Renin inhibitors
US4758584A (en) * 1987-02-05 1988-07-19 Ciba-Geigy Corporation Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups
US5162497A (en) * 1987-09-24 1992-11-10 The Administrators Of The Tulane Educational Fund Bradykinin analogs with non-peptide bond
DE68916271T2 (de) * 1988-01-26 1995-02-23 Sankyo Co Renin inhibierende Polypeptide, ihre Herstellung und Anwendung.
WO1989009230A1 (en) * 1988-03-25 1989-10-05 Administrators Of The Tulane Educational Fund Therapeutic peptides
IL90872A0 (en) * 1988-07-08 1990-02-09 Smithkline Beckman Corp Retroviral protease binding peptides
US5688770A (en) * 1989-12-14 1997-11-18 Schering Corporation Antiglaucoma compositions and methods
US5869615A (en) * 1994-01-03 1999-02-09 Washington University Modified complement proteases
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6239273B1 (en) 1995-02-27 2001-05-29 Affymetrix, Inc. Printing molecular library arrays
US6046169A (en) * 1995-06-07 2000-04-04 Cor Therapeutics, Inc. Inhibitors of factor XA
US5721214A (en) * 1995-06-07 1998-02-24 Cor Therapeutics, Inc. Inhibitors of factor Xa
US5919765A (en) * 1995-06-07 1999-07-06 Cor Therapeutics, Inc. Inhibitors of factor XA
US6022861A (en) * 1995-06-07 2000-02-08 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
TR199701526T1 (xx) 1995-06-07 1998-03-21 Glaxo Group Limited Bir trombopoietin resept�r�ne ba�lanan peptitler ve bile�ikler.
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
FR2735983B1 (fr) 1995-06-29 1997-12-05 Centre Nat Rech Scient Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6245743B1 (en) 1996-06-05 2001-06-12 Cor Therapeutics, Inc. Inhibitors of factor Xa
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
US5972894A (en) * 1997-08-07 1999-10-26 Cytran, Inc. Peptides having potassium channel opener activity
US6984719B1 (en) 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
WO2000042071A2 (en) 1999-01-12 2000-07-20 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6682739B1 (en) 1999-07-28 2004-01-27 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclastogenesis
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
US7041465B1 (en) 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
CA2383456C (en) 1999-08-23 2016-06-07 Clive Wood Pd-1, a receptor for b7-4, and uses therefor
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
NZ528265A (en) 2001-04-02 2005-10-28 Wyeth Corp Screening of compounds which modulate PD-1 signalling by testing for compounds that modulate phosphorylation of SHP-2, ERK1 or ERK-2, and PKC-theta
KR20100094569A (ko) 2002-02-06 2010-08-26 비코르 테크놀로지스 인코포레이티드 경색방지 분자
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
US20050265992A1 (en) 2003-01-03 2005-12-01 The Research Foundation Of State University Of New York F11 receptor (F11R) antagonists as therapeutic agents
US8557957B2 (en) 2003-01-03 2013-10-15 Elizabeth Kornecki Methods of treating disorders by administration of F11 receptor antagonists
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2536357A1 (en) 2003-05-29 2004-12-23 The Scripps Research Institute Targeted delivery to legumain-expressing cells
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
ZA200604869B (en) 2003-12-04 2007-11-28 Univ Utah Res Found Modified macromolecules and methods of making and using thereof
US20100330143A1 (en) 2003-12-04 2010-12-30 University Of Utah Research Foundation Modified macromolecules and methods of making and using thereof
EP1734982A4 (en) 2004-03-04 2009-08-05 Univ Vanderbilt Into the cell penetrating SOCS-POLYPEPTIDES THAT INHIBIT THE CYTOKININDUCED SIGNALING
KR20070050871A (ko) 2004-05-11 2007-05-16 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 그렐린을 사용하여 전염증성 사이토킨 발현을 억제하는방법
WO2005113582A1 (en) * 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
AU2005319155B2 (en) 2004-12-21 2013-01-31 Musc Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
US8158586B2 (en) 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
MX2007013430A (es) 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
EP2371843B1 (en) 2005-05-19 2014-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Functional epitopes of streptococcus pneumoniae psaA antigen and uses thereof
ES2729976T3 (es) 2005-06-07 2019-11-07 Dsm Nutritional Products Ag Microorganismos eucariotas para la producción de lípidos y antioxidantes
DK2439268T3 (en) 2005-06-16 2016-02-01 Dsm Nutritional Products Ag Immobilized enzymes and methods of use thereof
US8071554B2 (en) 2005-08-05 2011-12-06 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US20100041597A1 (en) 2005-08-05 2010-02-18 Jenny Phipps Peptides targeted to protein kinase c isoforms and uses thereof
JP5192384B2 (ja) 2005-09-22 2013-05-08 メディバス エルエルシー ビス−（α−アミノ）−ジオール−ジエステル含有ポリ（エステルアミド）およびポリ（エステルウレタン）組成物および使用の方法
JP5178520B2 (ja) 2005-09-22 2013-04-10 メディバス エルエルシー 固体ポリマー送達組成物およびその使用法
HUE031989T2 (en) 2005-10-04 2017-08-28 Soligenix Inc New peptides for the treatment and prevention of immune-related disorders, including treatment and prevention of infection by modulation of natural immunity
EP2392646A1 (en) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
ZA200804082B (en) 2005-11-07 2010-02-24 Scripps Research Inst Compositions and methods for controlling tissue factor signaling specificity
EP1954838B1 (en) 2005-11-14 2014-02-26 Life Technologies Corporation Coded molecules for detecting target analytes
EP2386639A3 (en) 2005-11-21 2012-05-30 Protox Therapeutics Incorporated Modified pore-forming protein toxins and use thereof
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
WO2007076537A2 (en) 2005-12-29 2007-07-05 The Regents Of The University Of California Methods and compositions related to mutant kunitz domain i of tfpi-2
EP2510943B1 (en) 2006-02-06 2016-04-20 The Burnham Institute for Medical Research Methods and compositions related to targeting tumors and wounds
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US8865398B2 (en) 2006-09-01 2014-10-21 Abbott Laboratories Combination hepatitis C virus antigen and antibody detection method
EP3034083B1 (en) 2006-09-21 2020-12-09 University of Rochester Antisense oligonucleotides for use in treating myotonic dystrophy
WO2008136852A2 (en) 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
US8637459B2 (en) 2006-11-08 2014-01-28 Emory University Enhancing a population of insulin releasing cells using GFR-A1 agonists
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008136869A2 (en) 2006-12-06 2008-11-13 Burnham Institute For Medical Research Methods and compositions related to targeting wounds, regenerating tissue, and tumors
WO2008085794A2 (en) 2007-01-03 2008-07-17 Burnham Institute For Medical Research Methods and compositions related to clot binding compounds
EP2101567A4 (en) 2007-01-18 2010-04-21 Univ Utah Res Found COMPOSITIONS AND METHODS FOR DETECTING, TREATING OR PREVENTING REDUCED STRESS
US8097588B2 (en) 2007-02-08 2012-01-17 Sanford-Burnham Medical Research Institute Trophinin-binding peptides and uses thereof
US9381226B2 (en) 2007-02-08 2016-07-05 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
WO2008101184A2 (en) 2007-02-16 2008-08-21 The Board Of Trustees Of Southern Illinois University Arl-1 specific antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
WO2009023306A2 (en) 2007-05-09 2009-02-19 Burnham Institute For Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
US8501912B2 (en) 2007-12-03 2013-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Filipil compositions and methods for treating cancer
KR101768792B1 (ko) 2008-01-22 2017-08-16 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
JP2011514160A (ja) 2008-02-21 2011-05-06 バーナム インスティテュート フォー メディカル リサーチ Ｃ末端エレメントを有するペプチドおよびタンパク質に関する方法および組成物
CN102083862A (zh) 2008-04-01 2011-06-01 康奈尔大学 有机-可溶性壳聚糖盐和由其制备的壳聚糖衍生生物材料
EP3447128A1 (en) 2008-06-04 2019-02-27 FUJIFILM Cellular Dynamics, Inc. Methods for the production of ips cells using non-viral approach
EP3045123B1 (en) 2008-06-16 2020-04-08 University Of Rochester Compositions comprising a combination of fibroblast growth factor (fgf) analogs with thrombopoietin for use for treating acute radiation syndrome
AU2008360658B2 (en) 2008-08-15 2015-02-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S0X9, prostaglandin D2 and retinoic acid for treating pigmentary conditions and melanoma
US8455438B2 (en) 2008-12-29 2013-06-04 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
ES2620478T3 (es) 2009-02-16 2017-06-28 Cerenis Therapeutics Holding Sa Miméticos de la apolipoproteína A-I
DK3150701T3 (en) 2009-06-05 2019-01-14 Fujifilm Cellular Dynamics Inc REPROGRAMMING T-CELLS AND HEMATOPOIETIC CELLS
US10370245B2 (en) 2009-06-22 2019-08-06 Sanford-Burnham Medical Research Institute Methods and compositions using peptides and proteins with C-terminal elements
US20120108514A1 (en) 2009-07-09 2012-05-03 University Of Iowa Research Foundation Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
US8409603B2 (en) 2009-10-01 2013-04-02 University Of South Carolina Compositions and methods for tissue engineering, tissue regeneration and wound healing
EP2496947A1 (en) 2009-11-04 2012-09-12 Novartis AG Positively charged species as binding reagents in the separation of protein aggregates from monomers
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
US8968740B2 (en) 2009-11-13 2015-03-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
CA2784145A1 (en) 2009-12-18 2011-06-23 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
IT1397901B1 (it) 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US9631018B2 (en) 2010-03-26 2017-04-25 The Trustees Of Dartmouth College Vista regulatory T cell mediator protein, vista binding agents and use thereof
WO2011127405A1 (en) 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Methods and compositions for enhanced delivery of compounds
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
WO2012135385A1 (en) 2011-03-28 2012-10-04 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
CA2837588A1 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
WO2012170356A1 (en) 2011-06-04 2012-12-13 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
WO2013010045A1 (en) 2011-07-12 2013-01-17 Biotime Inc. Novel methods and formulations for orthopedic cell therapy
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
CN103906761B (zh) 2011-08-30 2016-12-21 梅约医学教育与研究基金会 利钠多肽
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
KR101855242B1 (ko) 2012-01-26 2018-05-09 크리스토퍼 제이. 소레스 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
WO2013130808A1 (en) 2012-02-29 2013-09-06 D.E. Shaw Research, Llc Methods for screening voltage gated proteins
WO2013154771A1 (en) 2012-04-12 2013-10-17 Georgia Regents University Redox-resistant nitric oxide synthase
WO2013162748A1 (en) 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
EP3613765A1 (en) 2012-08-03 2020-02-26 Dana-Farber Cancer Institute, Inc. Antibody against repulsive guidance molecule b (rgmb)
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
DK2996706T3 (da) 2013-03-14 2019-10-21 Uab Research Foundation Apolipoprotein-mimetika og anvendelser deraf
WO2014201118A2 (en) 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
WO2015017529A2 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
AU2015206603B9 (en) 2014-01-14 2019-07-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
MX2016016310A (es) 2014-06-11 2017-10-20 A Green Kathy Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
SI3154594T1 (sl) 2014-06-13 2023-10-30 Bach Biosciences, Llc FAP-aktivirana terapevtska sredstva in z njimi povezane uporabe
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
US11642391B2 (en) 2014-08-06 2023-05-09 Vascular Biosciences Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same
US10189878B2 (en) 2014-09-24 2019-01-29 University Of Utah Research Foundation Ebolavirus pre-hairpin intermediate mimics and methods of use
WO2016090347A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
CA2968352A1 (en) 2014-12-08 2016-06-16 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
US10765754B2 (en) 2015-08-28 2020-09-08 Navigen, Inc. Compositions and methods related to inhibition of respiratory syncytial virus entry
EP3362074B1 (en) 2015-10-16 2023-08-09 President and Fellows of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
US11034739B2 (en) 2015-11-13 2021-06-15 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases
CN116920085A (zh) 2016-02-12 2023-10-24 詹森药业有限公司 抗-vista（b7h5）抗体
CN109789201B (zh) 2016-04-15 2023-06-16 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
ES2965087T3 (es) 2016-09-02 2024-04-10 Soares Christopher J Uso de antagonistas de receptor de CGRP en el tratamiento de glaucoma
EP3512564B1 (en) 2016-09-14 2024-01-17 The Trustees of The University of Pennsylvania Proximity-based sortase-mediated protein purification and ligation
WO2018089601A1 (en) 2016-11-09 2018-05-17 Mayo Foundation For Medical Education And Research Manp analogues
AR111842A1 (es) 2017-06-02 2019-08-21 Amgen Inc Antagonistas de péptido pac1
US11466231B2 (en) 2018-06-05 2022-10-11 Dsm Ip Assets B.V. Process for the production of diglycerides
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1585061A (en) * 1977-03-15 1981-02-25 Nat Res Dev Synthesis of peptides
US4198398A (en) 1977-07-12 1980-04-15 Derek Hudson Enkephalin analogues

Also Published As

Publication number Publication date
FI812427L (fi) 1982-02-07
AU549157B2 (en) 1986-01-16
ES8305306A1 (es) 1983-04-01
AU7381581A (en) 1982-02-11
DE3172138D1 (en) 1985-10-10
IE811785L (en) 1982-02-06
EP0045665A1 (en) 1982-02-10
EP0045665B1 (en) 1985-09-04
IE51471B1 (en) 1986-12-24
NO812612L (no) 1982-02-08
US4424207A (en) 1984-01-03
DK349481A (da) 1982-02-07

Similar Documents

Publication Publication Date Title
ES504575A0 (es) Procedimiento para preparar isosteros de polipeptidos inhibi dores de renina.
ES507715A0 (es) Procedimiento para preparar derivados de 1-sulfo-2-oxoazetidina .
ES507126A0 (es) Procedimiento para preparar derivados de piridona.
ES508060A0 (es) Procedimiento para preparar amidas tetrapeptidas n-adamantano-sustituidas.
AR231137A1 (es) Procedimiento para preparar metoxifenetilimidazoles
ES516154A0 (es) Procedimiento para preparar polipeptidos.
IT1116742B (it) Procedimento per la preparazione di bis-immidi aromatiche
MX161186A (es) Procedimiento para preparar peptidos
ES523733A0 (es) Procedimiento para preparar acilanilidas.
ES523064A0 (es) Procedimiento para preparar azetidinas.
ES506842A0 (es) Procedimiento para preparar derivados 3-aminopropoxifenili- cos.
ES502851A0 (es) Procedimiento para preparar n6-adenosina
ES521813A0 (es) Procedimiento para preparar alcohil-polisacaridos.
ES520531A0 (es) Procedimiento para preparar tioeteres.
ES500738A0 (es) Procedimiento para preparar pirimidil-quinazolinas
MX6699E (es) Procedimiento para preparar acil-ureas
MX6807E (es) Procedimiento para preparar oxaquinolicidinas
MX5194E (es) Procedimiento para preparar 3-aminometi-4-beta-hidroxi-8-beta-alcoxi-2,9-dioxatriciclo(4,3,1,03,7)decano
AR226337A1 (es) Procedimiento para preparar kijanimicina
AR227304A1 (es) Procedimiento para preparar tiazoles
ES498762A0 (es) Procedimiento para preparar benzonitrilos sustuituidos
ES513070A0 (es) Procedimiento para preparar butirotiolactonas.
ES514364A0 (es) Procedimiento para preparar 2-cianoesteroides.
NO157221C (no) Fremgangsmaate for elektroplettering.
ES508259A0 (es) "procedimiento para preparar tiocarnitinas".